| Literature DB >> 36178723 |
Xiaoyou Su1, Yu Jiang1, Mingyu Si1, Wenjun Wang2, Xi Zhang3, Xiaofen Gu4, Li Ma5, Jing Li6, Shaokai Zhang7, Zefang Ren8, Yuanli Liu9, Youlin Qiao1.
Abstract
BACKGROUND: Patients diagnosed with cervical cancer in the last 2 decades were mainly young females. Human papillomavirus (HPV) vaccination is the most radical way to prevent HPV infection and cervical cancer. However, most female college students in mainland China have not yet been vaccinated, and their relevant knowledge is limited. Theory-based education delivered via the internet is a potentially accessible and useful way to promote HPV vaccination among this population.Entities:
Keywords: China; female college students; human papillomavirus vaccination; information-motivation-behavioral skills model; internet-based education
Mesh:
Substances:
Year: 2022 PMID: 36178723 PMCID: PMC9568820 DOI: 10.2196/37848
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 7.076
Cover pages, contents, and purposes of the information-motivation-behavioral skills model–based 7-day education.
| Serial number | Cover page | Content | Examples of the quizzes | Purpose |
| 1 |
| General facts about HPVa, including HPV infection and related diseases. For example, there are more than a hundred different types of HPV, some of which are high risk and linked to the development of cancers, including cervical cancers. | 1. What is the transmission route of HPV? | To provide a general overview of the topic, by attracting the subjects’ attention with interesting animations. |
| 2 |
| Frequently asked questions and answers about HPV vaccine. For example, how does the HPV vaccine work? What are the recommended ages and populations for vaccination? | 1. True or false: | To convey relevant messages to improve the subjects’ understanding of HPV vaccines and vaccination. |
| 3 |
| A story of a female movie star who died of cervical cancer. Then, a case of a woman who missed HPV vaccination and cervical cancer screening, reached the terminal stage of cancer right after being found symptomatic, and died after painful treatment. Finally, the relevant facts about the screening, treatment, and prognosis of cervical cancer. | 1. True or false: Persistent HPV infection may cause cervical cancer. | To use real-life experiences to stimulate the participants’ fear and susceptibility to cervical cancer and arouse their desire to be vaccinated against HPV. |
| 4 |
| Risk factors and early symptoms of cervical cancer, and ways to prevent and control cervical cancer. | 1. Regarding the high-risk factors of cervical cancer, which of the following is wrong? | To call for HPV vaccination and regular cervical cancer screening, in order to arouse the desire of participants to get vaccinated against HPV. |
| 5 |
| The concept and practice of decision-making and effective communication. | 1. Application information: Please select the views that support HPV vaccination (multiple choices) | To make firm the participants’ determination to receive HPV vaccines, and communicate effectively with parents and friends to obtain support. |
| 6 |
| The concept and function of self-efficacy, evaluation of self-efficacy, and ways to improve self-efficacy. | What are the ways to improve self-efficacy (multiple choices)? | To provide guidance on how to improve self-efficacy and turn the idea of HPV vaccination into action. |
| 7 |
| Provide participants with the objective skills needed for HPV vaccination in the form of invitation letters designed with HTML5 front-end technology, such as appointment platform, price, vaccination venue, etc. | The last page is linked to the online questionnaire after the intervention. | To provide detailed objective information required for HPV vaccination, making HPV vaccination more accessible and convenient. |
aHPV: human papillomavirus.
Figure 1The study flowchart.
Baseline characteristics of the participants.
| Variable | All (N=3484) | Intervention group | Control group | |||
| Age (years), mean (SD) | 19.12 (0.73) | 19.12 (0.72) | 19.11 (0.73) | 0.34a (3482) | .73 | |
|
|
|
|
| 0.73 (1) | .39 | |
|
| Arts | 1848 (53.0) | 961 (53.8) | 887 (52.3) |
|
|
|
| Science | 1636 (47.0) | 827 (46.3) | 809 (47.7) |
|
|
|
|
|
|
| 0.25 (1) | .62 | |
|
| Han | 3057 (87.7) | 1564 (87.5) | 1493 (88.0) |
|
|
|
| Other | 427 (12.3) | 224 (12.5) | 203 (12.0) |
|
|
|
|
|
|
| 1.32 (1) | .25 | |
|
| Urban | 2207 (63.4) | 1149 (64.3) | 1058 (62.4) |
|
|
|
| Rural | 1277 (36.7) | 639 (35.7) | 638 (37.6) |
|
|
|
|
|
|
| 1.05 (1) | .31 | |
|
| Urban | 2189 (62.8) | 1138 (63.7) | 1051 (62.0) |
|
|
|
| Rural | 1295 (37.2) | 650 (36.4) | 645 (38.0) |
|
|
|
|
|
|
| 0.97 (2) | .62 | |
|
| Junior high school or less | 1591 (45.7) | 1428 (79.9) | 1391 (82.0) |
|
|
|
| Senior high school or technical secondary school | 1037 (29.8) | 120 (6.7) | 119 (7.0) |
|
|
|
| College or more | 856 (24.6) | 189 (10.6) | 151 (8.9) |
|
|
|
|
|
|
| 5.29 (3) | .15 | |
|
| Married | 2819 (80.9) | 51 (2.9) | 35 (2.1) |
|
|
|
| Divorced/separated | 239 (6.9) | 831 (46.5) | 760 (44.8) |
|
|
|
| Unmarried cohabiting | 340 (9.8) | 524 (29.3) | 513 (30.3) |
|
|
|
| Widowed | 86 (2.5) | 433 (24.2) | 423 (24.9) |
|
|
|
|
|
|
| 5.49 (2) | .06 | |
|
| <1000 | 720 (20.7) | 392 (21.9) | 328 (19.3) |
|
|
|
| 1000-2000 | 2483 (71.3) | 1243 (69.5) | 1240 (73.1) |
|
|
|
| >2000 | 281 (8.1) | 153 (8.6) | 128 (7.6) |
|
|
|
|
|
|
| 0.78 (1) | .38 | |
|
| Yes | 842 (24.2) | 421 (23.6) | 421 (24.8) |
|
|
|
| No | 2642 (75.8) | 1367 (76.5) | 1275 (75.2) |
|
|
|
|
|
|
| 0.40 (1) | .53 | |
|
| Yes | 2758 (79.2) | 1423 (79.6) | 1335 (78.7) |
|
|
|
| No | 726 (20.8) | 365 (20.4) | 361 (21.3) |
|
|
|
|
|
|
| 0.38 (1) | .54 | |
|
| Yes | 590 (16.9) | 296 (16.6) | 294 (17.3) |
|
|
|
| No | 2894 (83.1) | 1492 (83.5) | 1402 (82.7) |
|
|
|
|
|
|
| 4.43 (1) | .04c | |
|
| Yes | 97 (2.8) | 60 (3.4) | 37 (2.2) |
|
|
|
| No | 3387 (97.2) | 1728 (96.6) | 1659 (97.8) |
|
|
|
|
|
|
| 0.29 (1) | .59 | |
|
| Yes | 1310 (37.6) | 680 (38.0) | 630 (37.2) |
|
|
|
| No | 2174 (62.4) | 1108 (62.0) | 1066 (62.9) |
|
|
aAnalysis for t test.
bA currency exchange rate of 1 RMB=US $0.14435 is applicable.
cSignificant P<.05.
Generalized estimating equation model of willingness and the 3 dimensions of the information-motivation-behavioral skills model regarding human papillomavirus vaccination between the intervention and control groups.
| Variablea | Willingness to receive the HPVb vaccine | Information | Motivation | Behavioral skills | ||||||||
|
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||
|
| No | Reference |
| Reference |
| Reference |
| Reference |
| |||
|
| Yes | 1.025 | <.001c | 1.037 | <.001c | 0.171 | <.001c | 0.137 | .01c | |||
|
|
|
|
|
|
|
|
|
| ||||
|
| T-baseline | Reference |
| Reference |
| Reference |
| Reference |
| |||
|
| T-postintervention | −0.019 | .67 | 0.391 | <.001c | −0.055 | <.001c | −0.029 | .006c | |||
|
| T-1 month | −0.055 | .27 | 0.628 | <.001c | −0.065 | <.001c | −0.043 | <.001c | |||
|
| T-3 months | 1.476 | <.001c | 0.762 | <.001c | −0.035 | <.001c | −0.017 | .23 | |||
|
|
|
|
|
|
|
|
|
| ||||
|
| Control | Reference |
| Reference |
| Reference |
| Reference |
| |||
|
| Intervention | 0.042 | .56 | 0.103 | .26 | 0.002 | .84 | 0.011 | .52 | |||
|
|
|
|
|
|
|
|
|
| ||||
|
| T-baseline × intervention/control | Reference |
| Reference |
| Reference |
| Reference |
| |||
|
| T-postintervention × intervention/control | 0.320 | <.001c | 2.202 | <.001c | 0.115 | <.001c | 0.104 | <.001c | |||
|
| T-1 month × intervention/control | 0.183 | .01c | 1.892 | <.001c | 0.085 | <.001c | 0.062 | <.001c | |||
|
| T-3 months × intervention/control | 0.140 | .13 | 1.688 | <.001c | 0.053 | <.001c | 0.059 | .003c | |||
aThe generalized estimating equation model was adjusted with the significant variable in the chi-square analysis of baseline data, namely “sexual debut.”
bHPV: human papillomavirus.
cSignificant P<.05.
dTime points: baseline (T-baseline), immediately after the intervention (T-postintervention), 1 month after the intervention (T-1 month), and 3 months after the intervention (T-3 months).
Main effect of the intervention on the willingness to undergo human papillomavirus vaccination from baseline to follow-up.
| Variable and timea | Intervention group | Control group | |||||||||||||||||
|
| Yes, n/N (%) | No, n/N (%) |
|
| Yes, n/N (%) | No, n/N (%) |
|
| |||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
|
| T-baselinee | 596/1788 (33.3) | 1192/1788 (66.7) | N/Af | N/A | 542/1696 (32.0) | 1154/1696 (68.0) | 0.75 (1) | .39 | ||||||||||
|
| T-postinterventione | 668/1654 (40.4) | 986/1654 (59.6) | 15.43 (1) | <.001g | 492/1559 (31.6) | 1067/1559 (68.4) | 27.11 (1) | <.001g | ||||||||||
|
| T-1 monthe | 591/1658 (35.7) | 1067/1658 (64.3) | 1.40 (1) | .24 | 481/1535 (31.3) | 1054/1535 (68.7) | 6.64 (1) | .01g | ||||||||||
|
| T-3 monthsh | 1092/1547 (70.6) | 455/1547 (29.4) | 368.59 (1) | <.001g | 968/1463 (66.2) | 495/1463 (33.8) | 6.81 (1) | .01g | ||||||||||
aTime points: baseline (T-baseline), immediately after the intervention (T-postintervention), 1 month after the intervention (T-1 month), and 3 months after the intervention (T-3 months).
bComparison between baseline and different follow-up time points in the intervention group.
cComparison between the intervention and control groups at baseline and each follow-up time point.
dHPV: human papillomavirus.
eAre you willing to get the HPV vaccine in recent months?
fN/A: not applicable.
gSignificant P<.05.
hAre you willing to get the HPV vaccine in the future?
Figure 2Trends of the mean scores of information (A), motivation (B), and behavioral skills (C) regarding human papillomavirus (HPV) vaccination in the intervention and control groups over time.
Main effect of the intervention on the mean scores of the information-motivation-behavioral skills model constructs regarding human papillomavirus vaccination from baseline to follow-up.
| IMBa model constructs and timeb | Intervention group, mean score (SD) | Mean difference within the group (95% CI) | Control group, mean score (SD) | Mean difference between groups (95% CI) | |||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||
|
| T-baseline | 5.29 (2.74) | N/Ae | N/A | N/A | 5.20 (2.72) | 0.93 (−0.09 to 0.27) | 1.00 (3482) | .32 | ||||||||
|
| T-postintervention | 7.92 (1.84) | 2.58 (2.43 to 2.74) | 32.70 (3448) | <.001f | 5.59 (2.86) | 2.33 (2.16 to 2.49) | 27.29 (3222) | <.001f | ||||||||
|
| T-1 month | 7.83 (2.07) | 2.51 (2.34 to 2.67) | 30.52 (3456) | <.001f | 5.87 (2.99) | 1.96 (1.78 to 2.14) | 21.46 (3213) | <.001f | ||||||||
|
| T-3 months | 7.73 (2.27) | 2.40 (2.22 to 2.57) | 27.25 (3368) | <.001f | 6.01 (3.02) | 1.72 (1.53 to 1.91) | 17.76 (3069) | <.001f | ||||||||
|
|
|
|
|
|
|
|
|
| |||||||||
|
| T-baseline | 3.24 (0.32) | N/A | N/A | N/A | 3.24 (0.32) | 0.00 (−0.02 to 0.03) | 0.39 (3482) | .70 | ||||||||
|
| T-postintervention | 3.31 (0.36) | 0.06 (0.03 to 0.08) | 4.81 (3448) | <.001f | 3.19 (0.32) | 0.12 (0.19 to 0.14) | 10.00 (3222) | <.001f | ||||||||
|
| T-1 month | 3.27 (0.35) | 0.02 (−0.01 to 0.04) | 1.50 (3456) | .13 | 3.18 (0.35) | 0.09 (0.07 to 0.11) | 7.31 (3213) | <.001f | ||||||||
|
| T-3 months | 3.26 (0.37) | 0.01 (−0.02 to 0.03) | 0.59 (3368) | .56 | 3.20 (0.36) | 0.05 (0.03 to 0.08) | 4.01 (3069) | <.001f | ||||||||
|
|
|
|
|
|
|
|
|
| |||||||||
|
| T-baseline | 3.66 (0.52) | N/A | N/A | N/A | 3.65 (0.52) | 0.01 (−0.02 to 0.05) | 0.74 (3482) | .46 | ||||||||
|
| T-postintervention | 3.74 (0.57) | 0.07 (0.03 to 0.10) | 3.70 (3448) | <.001f | 3.62 (0.55) | 0.12 (0.08 to 0.16) | 6.04 (3222) | <.001f | ||||||||
|
| T-1 month | 3.68 (0.56) | 0.01 (−0.03 to 0.05) | 0.60 (3456) | .55 | 3.61 (0.55) | 0.067 (0.03 to 0.11) | 3.54 (3213) | <.001f | ||||||||
|
| T-3 months | 3.70 (0.57) | 0.02 (−0.02 to 0.05) | 0.85 (3368) | .39 | 3.63 (0.58) | 0.07 (0.02 to 0.11) | 3.16 (3069) | <.001f | ||||||||
aIMB: information-motivation-behavioral skills.
bTime points: baseline (T-baseline), immediately after the intervention (T-postintervention), 1 month after the intervention (T-1 month), and 3 months after the intervention (T-3 months).
cComparison between baseline and different follow-up time points in the intervention group.
dComparison between the intervention and control groups at baseline and each follow-up time point.
eN/A: not applicable.
fSignificant P<.05.
Perceptions of the barriers and facilitators of receiving the human papillomavirus vaccine.
| Variable | All, n (%) | Intervention group, n (%) | Control group, n (%) | |||||
|
|
|
|
| |||||
|
|
|
|
|
| ||||
|
|
| Yes | 2060 (68.4) | 1092 (70.6) | 968 (66.2) | |||
|
|
| No | 950 (31.6) | 455 (29.4) | 495 (33.8) | |||
|
|
|
|
|
| ||||
|
|
| Yes | 2780 (90.5) | 1447 (91.5) | 1333 (89.5) | |||
|
|
| No | 291 (9.5) | 135 (8.5) | 156 (10.5) | |||
|
|
|
|
|
| ||||
|
|
| Do not know much about the HPV vaccine | 318 (18.8) | 119 (13.8) | 199 (24.0) | |||
|
|
| Unsure of its safety and effectiveness | 406 (24.0) | 171 (19.8) | 235 (28.3) | |||
|
|
| Worried about its side effects | 471 (27.8) | 210 (24.3) | 261 (31.4) | |||
|
|
| Possible needle injury | 178 (10.5) | 82 (9.5) | 96 (11.6) | |||
|
|
| Expensive | 433 (25.6) | 228 (26.4) | 205 (24.7) | |||
|
|
| Too many needles | 123 (7.3) | 68 (7.9) | 55 (6.6) | |||
|
|
| No sexual behavior | 279 (16.5) | 142 (16.5) | 137 (16.5) | |||
|
|
| Others | 19 (1.1) | 14 (1.6) | 5 (0.6) | |||
|
|
|
|
| |||||
|
|
|
|
|
| ||||
|
|
| Yes | 2760 (89.9) | 1425 (90.1) | 1335 (89.7) | |||
|
|
| No | 311 (10.1) | 157 (9.9) | 154 (10.3) | |||
|
|
|
|
|
| ||||
|
|
| Efficacy/effectiveness | 507 (16.5) | 259 (16.4) | 248 (16.7) | |||
|
|
| Safety | 856 (27.9) | 436 (27.6) | 420 (28.2) | |||
|
|
| Side effects | 543 (17.7) | 254 (16.1) | 289 (19.4) | |||
|
|
| Price | 786 (25.6) | 425 (26.9) | 361 (24.2) | |||
|
|
| Procedure for appointment and HPV vaccination | 250 (8.1) | 135 (8.5) | 115 (7.7) | |||
|
|
| Nothing to worry about | 94 (3.1) | 57 (3.6) | 37 (2.5) | |||
|
|
|
|
|
| ||||
|
|
| Insufficient message from the government | 1660 (54.1) | 821 (51.9) | 839 (56.4) | |||
|
|
| Too expensive | 2330 (75.9) | 1230 (77.8) | 1100 (73.9) | |||
|
|
| Not covered by medical insurance | 1718 (55.9) | 874 (55.3) | 844 (56.7) | |||
|
|
| Not included in national immunization programs | 1587 (51.7) | 806 (51.0) | 781 (52.5) | |||
|
|
| Inconvenient to schedule vaccination | 1218 (39.7) | 611 (38.6) | 607 (40.8) | |||
|
|
| Insufficient experience of doctors | 770 (25.1) | 360 (22.8) | 410 (27.5) | |||
|
|
| Vaccine hesitancy | 769 (25.0) | 374 (23.6) | 395 (26.5) | |||
|
|
| HPV vaccine–related stigma | 550 (17.9) | 266 (16.8) | 284 (19.1) | |||
|
|
|
|
|
| ||||
|
|
| Improve doctor’s recommendation | 2341 (76.2) | 1189 (75.2) | 1152 (77.4) | |||
|
|
| Media publicity | 1793 (58.4) | 908 (57.4) | 885 (59.4) | |||
|
|
| Make it convenient to schedule vaccination | 1994 (64.9) | 1036 (65.5) | 958 (64.3) | |||
|
|
| Provide the vaccine at a reasonable price | 2453 (79.9) | 1271 (80.3) | 1182 (79.4) | |||
|
|
|
|
| |||||
|
| 2-valent HPV (Cervarix, GlaxoSmithKline ) | 552 (18.3) | 287 (18.6) | 265 (18.1) | ||||
|
| 4-valent HPV (Gardasil, Merck and Co, Inc) | 425 (14.1) | 224 (14.5) | 201 (13.7) | ||||
|
| 9-valent HPV (Gardasil 9, Merck and Co, Inc) | 947 (31.5) | 489 (31.6) | 458 (31.3) | ||||
|
| 2-valent HPV (Cecolin, Innovax) | 1087 (36.1) | 548 (35.4) | 539 (36.8) | ||||
|
|
|
|
| |||||
|
|
|
|
|
| ||||
|
|
| Yes | 2839 (94.3) | 1465 (94.7) | 1374 (93.9) | |||
|
|
| No | 171 (5.7) | 82 (5.3) | 89 (6.1) | |||
|
|
|
|
|
| ||||
|
|
| Yes | 2862 (95.1) | 1471 (95.1) | 1391 (95.1) | |||
|
|
| No | 148 (4.9) | 76 (4.9) | 72 (4.9) | |||
|
|
|
|
|
| ||||
|
|
| Yes | 2887 (95.9) | 1492 (96.4) | 1395 (95.4) | |||
|
|
| No | 123 (4.1) | 55 (3.6) | 68 (4.6) | |||
aHPV: human papillomavirus.
bI: number of participants in the intervention group.
cC: number of participants in the control group.